satoreotide

Satoreotide is a third-generation, high-affinity somatostatin receptor type 2 (SSTR2) antagonist peptide developed as a radiopharmaceutical for both diagnostic and therapeutic purposes in oncology. It is designed to be conjugated with radioactive isotopes such as lutetium‑177 or actinium‑225, enabling targeted delivery of cytotoxic radiation to tumors that overexpress SSTR2. Unlike earlier somatostatin analogues, satoreotide acts as an antagonist at the SSTR2 receptor, which enhances tumor uptake and retention compared to agonists like DOTA-TATE. Preclinical and early clinical studies have demonstrated superior anti-tumor efficacy and tolerability in models of small cell lung cancer (SCLC), neuroendocrine tumors (NETs), pancreatic cancers, and Merkel cell carcinoma (MCC). Satoreotide-based radiopharmaceuticals are being developed by Ariceum Therapeutics for use as 'theranostic' agents—combining diagnostic imaging with targeted radionuclide therapy[1][3][5][6][8].

Other names

satoreotide trizoxetansatoreotide tetraxetan